Pfizer (PFE) Gets a Hold Rating from J.P. Morgan

By Carrie Williams

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFEResearch Report) today and set a price target of $46. The company’s shares closed yesterday at $39.38.

According to, Schott has 0 stars on 0-5 star ranking scale with an average return of -7.9% and a 37.7% success rate. Schott covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Mylan Inc, and Allergan.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $49.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $46.47 and a one-year low of $34.37. Currently, Pfizer has an average volume of 24.61M.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. Most recently, in February 2019, Mikael Dolsten, the President R&D of PFE bought 309,462 shares for a total of $9,516,355.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.